Sinaptica Therapeutics initiates Phase 2 connectome-guided TMS for Alzheimer's across 6 Italian and German centers
Summary
Italian TMS startup Sinaptica Therapeutics initiated their Phase 2 trial of connectome-guided personalized TMS for Alzheimer's disease across 6 centers in Italy and Germany, following their €25M Series B led by EQT Life Sciences. The trial uses individual patient resting-state fMRI connectivity maps to personalize TMS coil positioning and frequency targeting for each patient's unique default mode network architecture. Progress highlighted in the April 2026 Neurotech Notables.
Why it matters
Sinaptica initiating a multi-center European Phase 2 with EQT Life Sciences backing is the strongest possible execution signal for connectome-guided TMS. Moving from single-center feasibility to a 6-center randomized trial in one step reflects high confidence from both the investigators and investors in the scientific and commercial case for this approach.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial